Launching Biotechnology through Entrepreneurship
Visiting the MIDI Innovation Vault for episode three of our Podcast series exploring the global MedTech and Biotech Accelerators, Incubator Labs, and Development Communities communities, MIDI Principal Greg Montalbano welcomed guests Steve Chambers and Julie Wolf from IndieBio. Together, they give the listener an inner look at the New York-based development community looking to accelerate and support the next generation of entrepreneurial innovators in medical and biotechnology.
LISTEN TO THE IndieBio PODCAST HERE
The following is MIDI’s IndieBio’s podcast episode Executive Summary from the series titled:
The Deep Dive into Medical Accelerator & Incubator Labs
IndieBio and Executive Leadership Overview:
The IndieBio ecosystem is an all-inclusive launching pad for startups just setting out on their entrepreneurial journey. With the mission of pulling scientists into the fray of medical technology, they de-risk both the business and technical challenges of starting a company by providing their groups with funding, mentorship, lab space, and more, meanwhile offering access to a vast network of contacts and partners to connect them with the commercial world.
As Managing Director, Steve nurtures relationships between IndieBio founders, investors, mentors, and partners, drawing upon his impressive entrepreneurial background while chasing a lifelong passion for startup life. Finding himself attracted to business after earning his Ph.D. in Molecular Biology, Steve was a founding scientist at Vertex Pharmaceuticals before co-founding APRO Therapeutics. He is also a co-founder of BioStar, the UK’s first life science accelerator.
Julie, IndieBio’s Chief Science Officer, is a scientist turned entrepreneur, communications agent, and business coach. With a Ph.D. in Microbiology and fifteen years of experience in research, her previous work building communities of academics, nonprofits, and startups around science education, applications, and entrepreneurship prepared her for her role today promoting IndieBio’s founders and their breakthrough technologies.
IndieBio’s Rapid Work…Rapid Growth
As mentors, IndieBio emphasizes teaching their startups the cadence of entrepreneurial life, pushing them to not only find the best applications of their technology but the best methods of scaling their business as well.
With a term of only four months, the IndieBio program is a fast-paced, high-intensity program meant to reflect the conditions of the biotechnology industry and drive companies to advance. IndieBio views themselves as investors in their member companies; while providing ample funding and access to valuable lab resources, they hold founders accountable with an established reporting structure and continuously pressure them to make decisions and take action. With entrepreneurs often coming from heavily academic backgrounds, this guidance serves to reframe their view of success to include measurable business growth and technical achievement.
Along with its quick pace, IndieBio’s program also reflects the constant advancement of the medical device field, being offered twice a year and accepting ten companies from applications open to any interested startup. The ecosystem represents the ideal springboard for companies looking to get their technology into the hands of users while growing rapidly in the process.
To learn more about IndieBio and the other accelerators, incubator labs, and development communities helping the research of today become the cutting-edge medical technology of tomorrow, visit the MIDI Innovation Vault: https://info.midipd.com/podcast
If you have any questions or comments about MIDI, IndieBio, or would like to schedule a complimentary consultation with Greg Montalbano about your business, you can reach him by phone at 1-631-467-8686 or email at innovation@midipd.com.
If you enjoyed this blog content please follow MIDI on social media or if you would like to download informative industry-related white papers and supporting material please visit MIDI’s website at www.midipd.com.